What is CJC-1295?
CJC-1295 is a synthetic peptide analog of growth-hormone-releasing hormone (GHRH). In the research literature, it is studied for its effect on the pituitary GH signaling axis. Note that CJC-1295 exists in two research forms — with and without DAC (drug-affinity complex) — which alter its pharmacokinetic profile in published studies.
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide categorized in the research literature as a selective growth-hormone secretagogue (GHRP). Preclinical studies have examined its selectivity for GH release relative to other hormones. Human clinical evidence remains investigational.
Why are they discussed together?
In the peer-reviewed and semi-clinical literature, CJC-1295 and Ipamorelin are sometimes co-referenced because they act on distinct receptors in the GH signaling axis. This combined pharmacological framing is a research topic — it is not equivalent to a human protocol recommendation.
Regulatory context
Both compounds are treated as investigational research peptides in the U.S. The FDA has issued guidance restricting certain peptides from compounding pharmacy Category 503A/503B lists. Growth-hormone secretagogues are also under WADA scrutiny for competitive sport.
Documented safety variables
The most cited variables in the literature and regulatory commentary are: sourcing purity in the unregulated research-chemical market, absence of long-term human safety data, potential endocrine effects that require professional medical monitoring, and legality of possession in the user's jurisdiction.